Only five weeks to go until DDL2022!
Join us in Edinburgh from 7th - 9th December
Come and see us at stand #104, and if you would like an in-depth discussion about our technology or your project, get in touch to pre-book a meeting
Cambridge, UK – 31st October 2022: We are proud to be sponsoring the 2022 Drug Delivery to the Lungs Conference for a second time, alongside Aptar, AZ, GSK, and Kindeva.
We are excited to announce that we’ll be launching our new, innovative Quattrii dry powder inhaler (DPI) technology, which is twice as effective with high fill masses and at lower inspiratory effort than any other available DPI technology on the market.
The aim of this simple, low-cost, high-performance DPI technology is to significantly improve the lives of patients, by streamlining the drug product development process, saving time, effort and money in clinical trials and drug rollout. The Quattrii technology platform is finely tuned for low potency (high payload) molecules and is able to produce a highly consistent fine particle dose that is independent of inspiratory effort.
For example, at 2 kPa (low effort) and 100 mg fill mass, our technology is more than twice as effective at delivering drug to the lung compared to anything else that we have tested in the laboratory.
In the build-up to the conference, we will be posting a series of blogs about some of the challenges with current inhaler technology and the strides we have made to successfully overcome them.
It’s an exciting moment for us to offer our Quattrii DPI technology, paving the way for a major step change in the field of respiratory drug delivery.
Join us on Stand #104 to find out more, or pre-book a meeting here.